Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026
Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company

Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products

Fineline Cube Aug 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second...

Company Deals

EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction

Fineline Cube Aug 2, 2023

US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for...

Company Deals

GSK Partners with Zuellig Pharma for Vaccine Distribution and Cold-Chain Management in Asia-Pacific

Fineline Cube Aug 2, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a leading global vaccine manufacturer, has signed an agreement with Philippines-based...

Company Drug

Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance

Fineline Cube Aug 2, 2023

Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan

Fineline Cube Aug 2, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements...

Company Deals

GeneMind Biosciences Secures RMB 400 Million in Series C Financing to Expand Gene Testing

Fineline Cube Aug 2, 2023

Shenzhen-based DNA sequencer specialist, GeneMind Biosciences Co., Ltd, has reportedly raised RMB 400 million in...

Company Deals

Guangzhou Wondfo Biotech Partners with Indonesia’s Kimia Farma in IVD Field

Fineline Cube Aug 2, 2023

China-based Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482) has entered into a partnership with Indonesia’s...

Company Deals

InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs

Fineline Cube Aug 2, 2023

China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum...

Company Deals

Sansure Biotech Partners with Indonesian Firm for Localized Molecular Diagnostic Production

Fineline Cube Aug 2, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company R&D

Sinopharm Partners with Harbin Institute of Technology to Boost Biomedical Industry Innovation

Fineline Cube Aug 2, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Harbin...

Company Deals

NK Celltech and RongCan Biotech Partner to Advance mRNA NK Cell Therapy and LNP Delivery System

Fineline Cube Aug 2, 2023

Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a...

Company Drug

Abbisko Therapeutics Initiates Phase II Clinical Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor

Fineline Cube Aug 2, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the dosing of the first...

Company Deals

CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China

Fineline Cube Aug 2, 2023

US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with...

Company Drug

Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment

Fineline Cube Aug 2, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Company Deals

Shanghai Junshi Biosciences Partners with Zein Biotechnology for PCSK9 mAb Commercialization in China

Fineline Cube Aug 2, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a partnership with...

Company

MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline

Fineline Cube Aug 2, 2023

US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results...

Company

GluBio Pharmaceutical Secures $22 Million in A+ Round Financing to Advance Protein Degradation Drugs

Fineline Cube Aug 1, 2023

GluBio Pharmaceutical Co., Ltd., an emerging player in targeted protein degradation drug development, has announced...

Company Drug

GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer

Fineline Cube Aug 1, 2023

GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...

Company Drug

Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna

Fineline Cube Aug 1, 2023

US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA)...

Company Deals

Mindray Bio-Medical Electronics to Acquire Majority Stake in DiaSys Diagnostic Systems

Fineline Cube Aug 1, 2023

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical device company based in...

Posts pagination

1 … 517 518 519 … 689

Recent updates

  • Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics
  • Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC
  • Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China
  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Others

Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.